Abstract：Objective To study the clinical effect of calsurf, a domestic exogenous pulmonary surfactant, in the treatment of severe neonatal infectious pneumonia. Methods A total of 208 neonates with severe infectious pneumonia who hospitalized in 5 hospitals of China were enrolled. According to their parents' wishes on admission, these neonates were administered with conventional treatment (control group; n=81) and calsurf treatment + conventional treatment (calsurf treatment group, n=127). The two groups were compared in terms of the degree of oxygen dependence on admission, blood gas parameters before and after treatment, lung ultrasound results, duration of mechanical ventilation, length of hospital stay, hospital costs, complications and prognosis. Results Compared with the control group on admission, the calsurf treatment group had significantly higher inhaled oxygen concentration and partial pressure of carbon dioxide and significantly lower arterial partial pressure of oxygen and oxygenation index (P < 0.01). After 1 hour of treatment, both groups had significant improvements in the above indices (P < 0.05), and the improvements were more significant in the calsurf treatment group (P < 0.05). After 4-6 hours of calsurf administration, there was a significant reduction in the degree of pulmonary consolidation. The calsurf treatment group had significantly shorter duration of mechanical ventilation and length of hospital stay than the control group, while there was no significant difference in the incidence rate of complications between the two groups. The neonates of both groups had a good prognosis. Conclusions In neonates with severe infectious pneumonia, calsurf treatment can significantly improve oxygenation, reduce the degree of pulmonary consolidation, and shorten the duration of mechanical ventilation and length of hospital stay. Therefore, it should be considered in neonates with severe infectious pneumonia.
QIU Ru-Xin,LIU Xin,WANG Jia-Li et al. Clinical effect of exogenous pulmonary surfactant in the treatment of severe neonatal infectious pneumonia: a multicenter prospective clinical trial[J]. CJCP, 2019, 21(4): 327-331.
Sweet DG, Camielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome -2016 Update[J]. Neonatology, 2017, 111(2):107-125.
[2]
Walsh BK, Daigle B, DiBlasi RM, et al. AARC Clinical Practice Guideline. Surfactant replacement therapy:2013[J]. Respir Care, 2013, 58(2):367-375.
[3]
Polin RA, Carlo WA, Committee on Fetus and Newborn, et al. Surfactant replacement therapy for preterm and term neonates with respiratory distress[J]. Pediatrics, 2014, 133(1):156-163.
Facco M, Nespeca M, Simonato M, et al. In vivo effect of pneumonia on surfactant disaturated-phosphatidylcholine kinetics in newborn infants[J]. PLoS One, 2014, 9(12):e93612.
